Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, (8), CD001446

Corticosteroids for Guillain-Barré Syndrome

Affiliations
Review

Corticosteroids for Guillain-Barré Syndrome

Richard A C Hughes et al. Cochrane Database Syst Rev.

Update in

  • Corticosteroids for Guillain-Barré Syndrome
    RA Hughes et al. Cochrane Database Syst Rev 10 (10), CD001446. PMID 27775812. - Review
    According to moderate quality evidence, corticosteroids given alone do not significantly hasten recovery from GBS or affect the long-term outcome. According to very low q …

Abstract

Background: Guillain-Barré syndrome (GBS) is an acute paralysing disease caused by inflammation of the peripheral nerves, which corticosteroids would be expected to benefit.

Objectives: To examine the ability of corticosteroids to hasten recovery and reduce the long-term morbidity from GBS.

Search methods: We searched The Cochrane Neuromuscular Disease Group Specialized Register (1 November 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 4), CENTRAL (2011, Issue 4), MEDLINE (January 1966 to October 2011) and EMBASE (January 1980 to October 2011).

Selection criteria: We included randomised controlled trials (RCTs) or quasi-RCTs of any form of corticosteroid or adrenocorticotrophic hormone in GBS. Our primary outcome was change in disability grade on a seven-point scale after four weeks. Secondary outcomes included time from randomisation until recovery of unaided walking, time from randomisation until discontinuation of ventilation (for those ventilated), death, death or disability (inability to walk without aid) after 12 months, relapse, and adverse events.

Data collection and analysis: Two authors extracted the data independently.

Main results: No new trials were discovered in the new searches in June 2009 or November 2011. Six trials with 587 participants provided data for the primary outcome. According to moderate quality evidence, the disability grade change after four weeks in the corticosteroid groups was not significantly different from that in the control groups, mean difference (MD) 0.36 less improvement (95% confidence intervals (CI) 0.16 more to 0.88 less improvement). In four trials of oral corticosteroids with 120 participants in total, there was significantly less improvement after four weeks with corticosteroids than without corticosteroids, MD 0.82 disability grades less improvement (95% CI 0.17 to 1.47). In two trials with a combined total of 467 participants, there was no significant difference, MD 0.17 (95% CI -0.06 to 0.39) of a disability grade more improvement after four weeks with intravenous corticosteroids. According to moderate to high quality evidence, there were no significant differences between the corticosteroid-treated and the control groups in any of the secondary efficacy outcomes. Diabetes was significantly more common and hypertension significantly much less common in the corticosteroid-treated participants.

Authors' conclusions: According to moderate quality evidence, corticosteroids given alone do not significantly hasten recovery from GBS or affect the long-term outcome. According to low quality evidence oral corticosteroids delay recovery. Diabetes requiring insulin was significantly more common and hypertension less common with corticosteroids.

Update of

  • Corticosteroids for Guillain-Barré Syndrome
    RA Hughes et al. Cochrane Database Syst Rev (2), CD001446. PMID 20166061. - Review
    According to moderate quality evidence, corticosteroids given alone do not significantly hasten recovery from GBS or affect the long-term outcome. According to low qualit …

Similar articles

  • Corticosteroids for Guillain-Barré Syndrome
    RA Hughes et al. Cochrane Database Syst Rev 10 (10), CD001446. PMID 27775812. - Review
    According to moderate quality evidence, corticosteroids given alone do not significantly hasten recovery from GBS or affect the long-term outcome. According to very low q …
  • Corticosteroids for Guillain-Barré Syndrome
    RA Hughes et al. Cochrane Database Syst Rev (2), CD001446. PMID 20166061. - Review
    According to moderate quality evidence, corticosteroids given alone do not significantly hasten recovery from GBS or affect the long-term outcome. According to low qualit …
  • Corticosteroids for Guillain-Barré Syndrome
    RA Hughes et al. Cochrane Database Syst Rev (2), CD001446. PMID 16625544. - Review
    Limited evidence shows that oral corticosteroids significantly slow recovery from Guillain-Barré syndrome. Substantial evidence shows that intravenous methylprednisolone …
  • Corticosteroids for Treating Guillain-Barré Syndrome
    RA Hughes et al. Cochrane Database Syst Rev (3), CD001446. PMID 10908498. - Review
    Corticosteroids should not be used in the treatment of Guillain-Barré syndrome. If a patient with Guillain-Barré syndrome needs corticosteroid treatment for some other re …
  • Corticosteroids for Treating Guillain-Barré Syndrome
    RA Hughes et al. Cochrane Database Syst Rev (2), CD001446. PMID 10796795. - Review
    Corticosteroids should not be used in the treatment of Guillain-Barré syndrome. If a patient with Guillain-Barré syndrome needs corticosteroid treatment for some other re …
See all similar articles

Cited by 17 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback